Axel Grothey is an Oncology physician affiliated with Campbell Clinic. OpenAlex indexes 863 publications with 51,244 citations (h-index 76); ClinicalTrials.gov lists 4 registered studies matched to this name. By OpenAlex citation count, this profile ranks in the top 5% of Hematology / Oncology profiles in the findmyKOL directory.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
7945 Wolf River Blvd
Germantown, TN 38138
Telephone
901-683-0055Registry record last updated 4 Mar 2019.
Clinical trials
- Combination Chemotherapy Plus Bevacizumab With or Without Oxaliplatin in Treating Older Patients With Metastatic Colorectal Cancer
Sponsor: Alliance for Clinical Trials in Oncology
- Sorafenib and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
Sponsor: Alliance for Clinical Trials in Oncology
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
39 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Astellas Pharma Global DevelopmentProgram year20251 payment
- Ipsen Biopharmaceuticals, IncProgram year20254 payments
- Caris MPI, Inc.Program year20254 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
49%PD-1 inhibitor27.8%Pembrolizumab68%Nivolumab32%Part B, office-administered≥40 patientsMicrotubule Inhibitor7.9%Paclitaxel73%Docetaxel27%Part B, office-administered≥18 patients+ 6 more classes in this area
Blood & clotting
35.4%Iron, parenteral preparations18.8%Ferric carboxymaltose94%Ferric derisomaltose6%Part B, office-administered≥25 patientsErythropoiesis-stimulating Agent16.5%Darbepoetin alfa100%Part B, office-administered≥41 patients+ 1 more class in this area
Musculoskeletal
4.7%RANK Ligand Inhibitor4.6%Denosumab100%Part B, office-administered≥56 patientsBisphosphonate0.1%Zoledronic acid100%Part B, office-administered≥13 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
Similar KOLs
Other experts from the same institution or the same specialty.
Freddie Bray
Centre National de la Recherche Scientifique
Jacques Ferlay
Centre international de recherche sur le cancer
Hermann Brenner
German Cancer Research Center
Isabelle Soerjomataram
Centre international de recherche sur le cancer
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”